CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
Abstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of to...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2014-07-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/303 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241458567020544 |
|---|---|
| author | G. Seledtsova I. Ivanova S. Mamaev D. Seledtsov N. Malkova V. Seledtsov V. I. Seledtsov |
| author_facet | G. Seledtsova I. Ivanova S. Mamaev D. Seledtsov N. Malkova V. Seledtsov V. I. Seledtsov |
| author_sort | G. Seledtsova |
| collection | DOAJ |
| description | Abstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of total). Neurological improvement was observed in five cases (13%) from the vaccine-treated group. Of 22 control MS patients who did not receive the immunotherapy, only 6 persons (27%) exhibited stabilization of their clinical state. Clinical improvement was not detectable among this group of MS patients. A group of twenty-six MS patients was treated with Rebif, without evidence of disease progression in eleven cases (42%), and distinct neurological improvement noted in one patient (4%) from this group. One year after starting the vaccine therapy, a rise in serum IL-10 was detected in vaccine-treated patients, whereas IL-17 and IL-18 serum levels remained within the initial ranges. A correlation between the serum levels of anti-myelin antibodies and appropriate anti-idiotypic antibodies was revealed in these patients. In general, the results obtained suggest polyclonal T-cell vaccination as a potentially effective treatment approach, both at early and more advanced stages of the disorder. |
| format | Article |
| id | doaj-art-11d716334678400fa1244b5a38eb86b3 |
| institution | Kabale University |
| issn | 1563-0625 2313-741X |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj-art-11d716334678400fa1244b5a38eb86b32025-08-20T04:00:09ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2014-07-01141-210310810.15789/1563-0625-2012-1-2-103-108300CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSISG. Seledtsova0I. Ivanova1S. Mamaev2D. Seledtsov3N. Malkova4V. Seledtsov5V. I. Seledtsov6НИИ клинической иммунологии CО РАМН, г. НовосибирскНИИ клинической иммунологии CО РАМН, г. НовосибирскКлиническая больница № 85, МоскваНИИ клинической иммунологии CО РАМН, г. НовосибирскОбластной центр рассеянного склероза, г. НовосибирскБалтийский федеральный университет им. И. Канта, г. КалининградБалтийский федеральный университет им. И. Канта, г. КалининградAbstract. Thirty-nine patients with a progredient clinical form of chronic multiple sclerosis (MS) were subject to multiple immunization with autologous polyclonal T-cell vaccines. Two years after initiating the vaccine therapy, no evidence for disease progression was noted in 16 patients (41% of total). Neurological improvement was observed in five cases (13%) from the vaccine-treated group. Of 22 control MS patients who did not receive the immunotherapy, only 6 persons (27%) exhibited stabilization of their clinical state. Clinical improvement was not detectable among this group of MS patients. A group of twenty-six MS patients was treated with Rebif, without evidence of disease progression in eleven cases (42%), and distinct neurological improvement noted in one patient (4%) from this group. One year after starting the vaccine therapy, a rise in serum IL-10 was detected in vaccine-treated patients, whereas IL-17 and IL-18 serum levels remained within the initial ranges. A correlation between the serum levels of anti-myelin antibodies and appropriate anti-idiotypic antibodies was revealed in these patients. In general, the results obtained suggest polyclonal T-cell vaccination as a potentially effective treatment approach, both at early and more advanced stages of the disorder.https://www.mimmun.ru/mimmun/article/view/303т-cell vaccinationmultiple sclerosiscytokinesantimyelin antibodiesanti-idiotypic antibodies |
| spellingShingle | G. Seledtsova I. Ivanova S. Mamaev D. Seledtsov N. Malkova V. Seledtsov V. I. Seledtsov CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS Медицинская иммунология т-cell vaccination multiple sclerosis cytokines antimyelin antibodies anti-idiotypic antibodies |
| title | CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS |
| title_full | CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS |
| title_fullStr | CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS |
| title_full_unstemmed | CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS |
| title_short | CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS |
| title_sort | clinical and immunological aspects of t c ell based vaccine therapy in patients with progredient multiple sclerosis |
| topic | т-cell vaccination multiple sclerosis cytokines antimyelin antibodies anti-idiotypic antibodies |
| url | https://www.mimmun.ru/mimmun/article/view/303 |
| work_keys_str_mv | AT gseledtsova clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT iivanova clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT smamaev clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT dseledtsov clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT nmalkova clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT vseledtsov clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis AT viseledtsov clinicalandimmunologicalaspectsoftcellbasedvaccinetherapyinpatientswithprogredientmultiplesclerosis |